Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

159
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
159
Inflammation01:38

Inflammation

53.2K
Overview
53.2K
Inflammatory Response01:28

Inflammatory Response

1.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

496
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
496
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

4.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.8K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

375
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
375

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic viral infection aggravates white adipose tissue dysfunction and liver pathology in obesity.

Molecular metabolism·2026
Same author

Chronic High-Fat Diet Does Not Alter Overall Cancer Incidence in Trp53R270H/+ Mice.

Cancer research communications·2026
Same author

Sulfur partitioning from cysteine controls T cell proliferation and effector function.

Cell·2026
Same author

Quantitative and temporal analysis of autophagy: Differential Response to amino acid and glucose starvation.

PloS one·2026
Same author

The CCL17-CCR4 Axis Is Critical for Mutant STAT6-Mediated Microenvironmental Remodeling and Therapeutic Resistance in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Cancer immunology research·2025
Same author

A Polymeric Nanocarrier Platform for Rapid and Precise Fatty Acid Tracing in Cells.

ACS applied bio materials·2025

Related Experiment Video

Updated: Jun 13, 2025

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.5K

A backhanded complement: Prostacyclin turns inflammation off from the inside out.

Samuel E J Preston1, Russell G Jones1

  • 1Department of Metabolism and Nutritional Programming, Van Andel Institute, Grand Rapids, MI, USA.

Immunity
|June 11, 2025
PubMed
Summary
This summary is machine-generated.

T helper 1 (Th1) cell overactivity is controlled by a new lipid-switching mechanism. This process involves complement C5 and prostacyclin (PGI2) signaling, which boosts interleukin (IL)-1R2 to help Th1 cells contract after infection.

More Related Videos

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.5K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.5K

Related Experiment Videos

Last Updated: Jun 13, 2025

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.5K
Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.5K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.5K

Area of Science:

  • Immunology
  • Cellular Biology
  • Molecular Medicine

Background:

  • Hyperactive T helper 1 (Th1) cell responses can drive autoimmune pathology.
  • Effective resolution of Th1-driven inflammation requires timely contraction of these cells after pathogen clearance.

Purpose of the Study:

  • To elucidate the molecular mechanisms regulating Th1 cell contraction following immune activation.
  • To identify novel pathways involved in self-limiting Th1 immune responses.

Main Methods:

  • The study utilized mouse models and in vitro cell culture systems.
  • Investigated the role of complement C5, lipid mediators, and cytokine signaling in Th1 cell fate.

Main Results:

  • Defined a complement-C5-mediated lipid-class-switch mechanism essential for Th1 cell self-control.
  • Demonstrated that enhanced cell-intrinsic prostacyclin (PGI2) signaling promotes interleukin (IL)-1R2 production.
  • Showed that increased IL-1R2 expression facilitates Th1 cell contraction post-activation.

Conclusions:

  • Complement C5 signaling initiates a lipid-class switch that enhances PGI2 production in Th1 cells.
  • This PGI2 surge upregulates IL-1R2, leading to Th1 cell contraction and resolution of inflammation.
  • Identified a novel regulatory axis for controlling Th1-mediated pathology.